Cymbalta and Application site vesicles - a phase IV clinical study of FDA data

Summary:

Application site vesicles is reported as a side effect among people who take Cymbalta (duloxetine hydrochloride), especially for people who are female, 50-59 old, have been taking the drug for 10+ years also take Fentanyl, and have Pain.

The phase IV clinical study analyzes which people have Application site vesicles when taking Cymbalta. It is created by eHealthMe based on reports of 145,249 people who have side effects when taking Cymbalta from the FDA, and is updated regularly.

What is Cymbalta?

Cymbalta has active ingredients of duloxetine hydrochloride. It is often used in depression. eHealthMe is studying from 154,973 Cymbalta users. Check the latest studies of Cymbalta.

What is Application site vesicles?

Application site vesicles (small bubble within a cell at application site) is found to be associated with 273 drugs and 570 conditions by eHealthMe. Check the latest studies of Application site vesicles.

On Jul, 12, 2026

145,249 people reported to have side effects when taking Cymbalta.
Among them, 43 people (0.03%) have Application site vesicles.

Could Cymbalta cause Application site vesicles?

Among these 43 people:

How long have people been on Cymbalta when they have Application site vesicles? *

What is the gender of people who have Application site vesicles when taking Cymbalta? *

female: 71.43 %
male: 28.57 %

What is the age of people who have Application site vesicles when taking Cymbalta? *

What are other drugs people take besides Cymbalta? *

Fentanyl: 7 people, 16.28%
Percocet: 6 people, 13.95%
Gabapentin: 6 people, 13.95%
Neurontin: 6 people, 13.95%
Fentanyl Transdermal System: 6 people, 13.95%
Xanax: 5 people, 11.63%
Qutenza: 4 people, 9.30%
Topamax: 4 people, 9.30%
Lyrica: 4 people, 9.30%
Amitiza: 4 people, 9.30%

What are other side effects people have besides Application site vesicles? *

Application Site Erythema (redness of the skin at application site): 18 people, 41.86%
Application Site Pruritus (application site severe itching of the skin): 14 people, 32.56%
Application Site Irritation: 10 people, 23.26%
Application Site Exfoliation (application site removal of the oldest dead skin cells on the skin's outermost surface): 9 people, 20.93%
Application Site Rash: 8 people, 18.60%
Application Site Pain: 8 people, 18.60%
Application Site Discoloration: 6 people, 13.95%
Rashes (redness): 4 people, 9.30%
Fall: 4 people, 9.30%
Application Site Burn: 4 people, 9.30%

What are the existing conditions these people have? *

Pain: 14 people, 32.56%
Breakthrough Pain: 10 people, 23.26%
Sleep Disorder: 6 people, 13.95%
Muscle Spasms (muscle contraction): 5 people, 11.63%
Complex Regional Pain Syndrome (long lasting pain condition most often affecting one of the limbs (arms, legs, hands, or feet)): 4 people, 9.30%
Urinary Tract Infection: 3 people, 6.98%
Nerve Injury: 3 people, 6.98%
Back Pain: 3 people, 6.98%
High Blood Pressure: 3 people, 6.98%
Insomnia (sleeplessness): 3 people, 6.98%

* Approximation only. Some reports may have incomplete information.

Do you take Cymbalta and have Application site vesicles?

- Check whether Application site vesicles is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Cymbalta:

Cymbalta (154,973 reports)

Browse all side effects of Cymbalta:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Application site vesicles:

Application site vesicles (273 drugs)

Browse all the conditions that are associated with Application site vesicles:

Application site vesicles (570 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on duloxetine hydrochloride (the active ingredients of Cymbalta) and Cymbalta (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.